Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Keros Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($5.82) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the business posted ($1.33) EPS. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year.
Get Our Latest Research Report on Keros Therapeutics
Keros Therapeutics Price Performance
Shares of KROS opened at $11.41 on Wednesday. The company’s 50-day moving average is $35.23 and its 200-day moving average is $46.97. The firm has a market capitalization of $462.18 million, a PE ratio of -2.19 and a beta of 1.43. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.
Institutional Investors Weigh In On Keros Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Exchange Traded Concepts LLC acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $99,000. SG Americas Securities LLC bought a new position in Keros Therapeutics in the fourth quarter valued at approximately $388,000. Geode Capital Management LLC raised its position in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares in the last quarter. Barclays PLC lifted its stake in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in Keros Therapeutics during the third quarter worth $868,000. Institutional investors own 71.56% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
- Five stocks we like better than Keros Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- SAP’s Strong Momentum: A Bullish Setup for Investors
- How to Use the MarketBeat Excel Dividend Calculator
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Investing in Construction Stocks
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.